Skip to main content

Table 2 Correlation between risk factors and CD66c expression. The distribution of CD66cpos and CD66cneg cases (cutoff 20%) is shown. In addition, no difference was observed in the RFS of the risk-defined subsets based on the CD66c expression (log-rank test p-value > 0.05 in all analyses). Only patients treated by a single ALL BFM-95 protocol are shown here (n = 254).

From: Myeloid antigens in childhood lymphoblastic leukemia:clinical data point to regulation of CD66c distinct from other myeloid antigens

  CD66cpos cases CD66cneg cases p-value (chi-square)
All patients 109 145 N/A
Prednisone poor responder 9 12 n.s.
Prednisone good responder 100 133  
Initial leukocytosis = > 20 × 109/L 28 44 n.s.
Initial leukocytosis < 20 × 109/L 81 101  
TEL/AML1 2 77 P < 0.0001
BCR/ABL 7 1  
MLL/AF4 0 1  
Hyperdiploid 55 7  
Other genotype (not TEL/AML1, BCR/ABL, MLL/AF4 or hyperdiploidy) 45 59  
Age 1–5 59 88 n.s.
Age >5 50 57  
Standard risk group 40 58 n.s.
Intermediate risk group 54 72  
High risk group 15 15